Repligen (NASDAQ:RGEN) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Key Points

• Repligen reported quarterly EPS of $0.53, beating the consensus estimate of $0.46 by $0.07. The company posted a 5.29% net margin and 5.30% return on equity.
• Shares opened at $180.17, with a market capitalization of approximately $10.17 billion and a 52-week range of $100.99 to $198.87. The stock trades at a notably high P/E ratio of 246.81.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $175.71; recent targets ranged as high as $225.

Repligen (NASDAQ:RGEN - Get Free Report) issued its earnings results on Tuesday. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.07, Zacks reports. Repligen had a net margin of 5.29% and a return on equity of 5.30%.

Repligen Price Performance

Repligen stock opened at $180.17 on Tuesday. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $10.17 billion, a P/E ratio of 246.81, a PEG ratio of 3.23 and a beta of 1.08. The business has a 50-day moving average of $177.37 and a 200-day moving average of $144.96. Repligen has a 1 year low of $100.99 and a 1 year high of $198.87.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on RGEN shares. Barclays increased their price objective on shares of Repligen from $175.00 to $225.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. Benchmark raised shares of Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Evercore reiterated an "outperform" rating and set a $160.00 target price on shares of Repligen in a research report on Monday, July 6th. Zacks Research cut shares of Repligen from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 28th. Finally, UBS Group reissued a "buy" rating on shares of Repligen in a research note on Tuesday, September 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Repligen has an average rating of "Moderate Buy" and a consensus target price of $175.71.

About Repligen

Repligen Corporation NASDAQ: RGEN develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company's offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.